Label change expected for osteoporosis drugs Fosamax, Actonel and Boniva
Osteoporosis drugs need better labels indicating time limits, suggested by FDA panel, but how much time is yet to be determined – A US FDA advisory committee wants the health agency FDA to limit the duration of bisphosphonate therapy for treatment of osteoporosis. The panel could not agree on what that time limit should be. The panel also endorsed a label change for osteoporosis drugs.